Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.12%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +35.00%
#5 RedStone RedStone +28.08%
#6 Humanity Humanity +25.92%
#7 Codatta Codatta +22.12%
#8 Walrus Walrus +20.05%
#9 Enso Enso +18.97%
#10 Tutorial Tutorial +17.31%
Coin of the day
EXOD EXOD
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Clasificación en acciones #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Precio por acción
$0.117
Última sincronización: 2025-04-04
Capitalización bursátil
$2.45M
Cambio (1 día)
-13.59%
Cambio (1 año)
0.00%
País
US
Comercio Carmell Therapeutics Corporation (CTCX)

Categoría

Healthcare
Ratio P/S de Carmell Therapeutics Corporation (CTCX)
Ratio P/S al August 2026 TTM: 3.52
Según los informes financieros más recientes y el precio de las acciones de Carmell Therapeutics Corporation, el ratio P/S actual (TTM) es 3.52. Al final de 2023, el ratio P/S era 0.00.
Historial del ratio P/S de Carmell Therapeutics Corporation desde 2021 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 3.52 -99.90%
2024 3.48K 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 188.58%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 187.49%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 34.60%
BE